Table 2. Combinatorial effects of PI3K inhibitors on several cancers.
| PI3K inhibitors | Combination agents | Tumor types | Reference |
|---|---|---|---|
| SF1126 | Trastuzumab | HER-2 overexpressing breast cancer | 60 |
| Doxorubicin | Neuroblastoma | 61 | |
| GDC-0941 | Trastuzumab and pertuzumab | Her-2 specific breast cancer | 69 |
| Doxorubicin | Breast and ovarian cancer | 70 | |
| NVP-BEZ235 | AZD6244 | Melanoma | 82 |
| Gemcitabine | Pancreatic ductal adenocarcinoma | 172 | |
| Sorafenib | Renal cell carcinoma | 173 | |
| RAD001 | Non-small cell lung cancer | 174 | |
| Neuroendocrine tumors | 175 | ||
| GSK2126458 | Breast cancer | 176 | |
| Taxotere | Prostate cancer | 177 | |
| PD0325901 | Glioma | 178 | |
| Vincristine | Sarcoma | 92 | |
| XL147 | Erlotinib | Solid tumors | Bioportfolio.com |
| Trastuzumab or paclitaxel | Metastatic breast cancer | Exelixis.com | |
| XL765 | Temozolomide | Glioma | Exelixis.com |
| Erlotinib | Solid tumor |